VERA THERAPEUTICS INC
VERANASDAQπ #1882 by market capEarnings Feb 24 Β· PostUS Equity
ββ
Quote unavailableTrack VERA
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$1.84B
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
67.9%
High
π΅FCF Margin
-3659.1%
Thin
βοΈP/S Ratio
179.0x
Expensive
Otter Score
44
Weak
No chart data available for VERA.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $25.08 β $56.05
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 72.3M
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $10M
- P/E Ratio
- -4.3
- P/S Ratio
- 179.0x
- EPS (TTM)
- $-5.76
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +17.0%
VERA THERAPEUTICS INC
VERAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$315Mβ² +88.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$242Mβ² +78.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
64.2Mβ² +17.0% YoY
About VERA THERAPEUTICS INC
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Weak
44/100
Analyst data unavailable.
Latest News & Updates
News unavailable.